ArticleBMC psychiatry2026
The relationship between cognitive function and inflammatory-nutritional status in schizophrenia: cognitive impairment is inversely related to PNI and CALLY indices.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of bipolar disorder and schizophrenia in women with risk of gestational diabetes: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2026Pooled it
- Orally administered scallop-derived plasmalogens improve cognitive function in healthy middle-aged and older adults: a randomized, double-blind, placebo-controlled trial.Frontiers in nutrition · 2026Trial
- The interplay of niacin skin flush response with plasma MDA, TNOS, iNOS and clinical symptom severity in chronic schizophrenia.BMC psychiatry · 2026Article
- The association between metabolic dysfunction-associated fatty liver disease and left ventricular mass index in patients with schizophrenia with long-term hospitalization.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive impairment in patients with schizophrenia is one of the symptoms most closely associated with functional loss throughout the disease course. There is increasing evidence suggesting that inflammation and nutritional status may contribute to impaired cognitive functions. The C-reactive protein/albumin ratio (CRP/ALB), prognostic nutritional index (PNI), and C-reactive protein–albumin–lymphocyte index (CALLY index) are easily calculated composite biomarkers reflecting nutritional status and immune-inflammatory processes. This study investigated the associations of the CRP/ALB, PNI, and CALLY indices with cognitive impairment in patients with schizophrenia.
methodsA total of 131 individuals (88 schizophrenia patients and 43 healthy controls) were included. Cognitive assessment was performed via the Montreal Cognitive Assessment Scale (MoCA). On the basis of the MoCA, 26 patients had cognitive impairment (SCH-CI), and 62 were classified as schizophrenia patients with preserved cognitive function (SCH-R), and 43 constituted the healthy control (HC) group. Serum ALB, lymphocyte, and CRP levels were first measured. The CRP/ALB ratio, PNI, and CALLY indices were then calculated on the basis of these parameters. Group differences were assessed via statistical analyses.
resultsThe CRP/ALB ratio was significantly higher in both schizophrenia groups than in the HC group (p2 < 0.001; p3 < 0.001), whereas no significant difference was observed between the SCH-CI and SCH-R groups (p1 = 1.000). The CALLY index was significantly lower in both schizophrenia groups than in the HC group (p2 < 0.001; p3 < 0.001), with no significant unadjusted difference between SCH-CI and SCH-R (p1 = 0.200). PNI values were significantly lower in the SCH-CI group than in both the SCH-R (p1 = 0.008) and HC groups (p2 = 0.013), whereas no significant difference was observed between the SCH-R and HC groups (p3 = 1.000). In multivariable logistic regression analyses adjusted for age, sex, body mass index, smoking status, education year, depot antipsychotic use, and treatment duration, the CALLY index remained independently associated with cognitive impairment (OR = 0.112, 95% CI: 0.013–0.943, p = 0.044), whereas the association for PNI was attenuated to borderline significance (OR = 0.895, 95% CI: 0.800–1.001, p = 0.052). The CRP/ALB ratio was not independently associated with cognitive impairment (OR = 13.363, 95% CI: 0.147–1212.867, p = 0.260).
conclusionsCognitive impairment in schizophrenia may be associated with disturbances in inflammatory and immunonutritional status. Among the evaluated biomarkers, the CALLY index showed the most robust independent association with cognitive impairment after adjustment for relevant covariates, whereas the association for PNI was weaker. Although these markers are inexpensive and easily obtainable from routine laboratory parameters, their modest discriminatory performance suggests that they may be more useful as supportive or risk-stratification markers than as standalone diagnostic tools. Larger prospective studies are needed to validate their clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.